ADARx Pharmaceuticals, Inc.
No enriched coverage for $ADRX in the last 7 days.
Simeon George, through SR One Capital Management, disclosed a 9.3% stake in ADARx Pharmaceuticals (ADRX) post-IPO. The investment includes converted preferred shares and IPO purchases, with a 180-day lock-up period. SR One plans long-term growth and holds registration rights post-lock-up. ADRX completed its IPO on Sept. 28, 2026.
OrbiMed Advisors disclosed a 14.0% stake in ADARx Pharmaceuticals (ADRX) post-IPO, acquiring shares at $17 each. The investment firm stated its intent is for investment, not control, and may buy or sell shares in the future. OrbiMed and affiliated directors agreed to a 180-day lock-up on sales.
ADARx Pharmaceuticals (ADRX) announced the closing of an additional 3.94 million shares sold in its IPO, raising $513.2 million at $17 per share. Including a concurrent private placement, total gross proceeds reached $602.5 million. J.P. Morgan, Morgan Stanley, and others acted as underwriters.
Recent ADRX coverage spans insider activity, financial news and corporate actions.
In the last 30 days, ADRX insiders filed 13 SEC Form 4 transactions — 13 purchases ($87.7M) and no sales. The most active reporter was George Simeon with 3 filings.
The new large shareholder could support the stock price by limiting supply and signaling confidence, but the 180‑day lock‑up may also cap short‑term upside.
The new sizable stake may signal confidence and could attract other investors, potentially supporting the stock price.
The additional share issuance dilutes existing shareholders and increases supply, likely pressuring the stock price in the short term.
Insider purchase by a director may be viewed as confidence in the company.
Significant insider buying by a director suggests confidence and may lift the stock.
AlphAI scores every news story that mentions ADRX with an AI model for sentiment and relevance, and aggregates insider trades from ADARx Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Simeon George, through SR One Capital Management, disclosed a 9.3% stake in ADARx Pharmaceuticals (ADRX) post-IPO. The investment includes converted preferred shares and IPO purchases, with a 180-day lock-up period. SR One plans long-term growth and holds registration rights post-lock-up. ADRX completed its IPO on Sept. 28, 2026.
1 min readOrbiMed Advisors disclosed a 14.0% stake in ADARx Pharmaceuticals (ADRX) post-IPO, acquiring shares at $17 each. The investment firm stated its intent is for investment, not control, and may buy or sell shares in the future. OrbiMed and affiliated directors agreed to a 180-day lock-up on sales.
1 min readADARx Pharmaceuticals (ADRX) announced the closing of an additional 3.94 million shares sold in its IPO, raising $513.2 million at $17 per share. Including a concurrent private placement, total gross proceeds reached $602.5 million. J.P. Morgan, Morgan Stanley, and others acted as underwriters.
2 min readChimovits Erez purchased 61,516 indirectly-held shares of ADARx Pharmaceuticals, Inc. (ADRX) at $17.00 ($1.05M total) on 2026-09-28.
1 min readGORDON CARL L purchased 950,000 indirectly-held shares of ADARx Pharmaceuticals, Inc. (ADRX) at $17.00 ($16.15M total) across 3 trades on 2026-09-28.
1 min readORBIMED ADVISORS LLC purchased 950,000 indirectly-held shares of ADARx Pharmaceuticals, Inc. (ADRX) at $17.00 ($16.15M total) across 3 trades on 2026-09-28. Filed jointly with OrbiMed Capital GP VII LLC (Director), OrbiMed Israel GP II, L.P. (Director), OrbiMed Advisors Israel II Ltd (Director) and OrbiMed Genesis GP LLC (Director).
1 min readSR ONE CAPITAL MANAGEMENT, LLC purchased 1,600,000 indirectly-held shares of ADARx Pharmaceuticals, Inc. (ADRX) at $17.00 ($27.20M total) across 3 trades on 2026-09-28.
1 min readGeorge Simeon purchased 1,600,000 indirectly-held shares of ADARx Pharmaceuticals, Inc. (ADRX) at $17.00 ($27.20M total) across 3 trades on 2026-09-28.
1 min readADARx Pharmaceuticals raised $446.3 million in its upsized IPO, pricing 26.25 million shares at $17.00 each. The company, focused on RNA therapeutics, began trading on Nasdaq under 'ADRX'. It plans to use the proceeds to advance its pipeline, including treatments for genetic disorders and obesity. AbbVie will own 4.9% post-IPO.
2 min readADARx Pharmaceuticals, Inc. (ADRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On September 13, 2026, ADARx Pharmaceuticals, Inc. (the “Company”) entered into a Common Stock Purchase Agreement with AbbVie Inc. (the “Purchaser”) pursuant to which the Purchaser agreed to purchase (the “Private Placement”) a n
2 min read
